AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has introduced a care model designed to improve access to clinically supervised treatment. Based in Austin, the service provides evidence-based TRT, enclomiphene treatment, and erectile dysfunction medications prescribed by licensed U.S. clinicians, with medications fulfilled through licensed U.S. pharmacies.

Feel30 launches national telehealth TRT with at-home nurse blood draws.

Feel30 was founded on 22nd February 2025, by entrepreneur Thomas Phillips, who sought to address common problems in traditional hormone care, including long wait times, multiple in-person lab visits, slow or delayed pharmacy compounding, confusing pricing with hidden fees, and rigid schedules. 

Internal data from Feel30’s early patient population shows that 40% of men seek evaluation primarily due to sustained low energy compared to earlier stages of life, while 30% enroll after relocating to a new state and needing continuity of TRT care.

Service features include transparent all-inclusive pricing, quarterly at-home nurse blood draws, home or in-clinic lab flexibility, unlimited clinician consultations, discreet pharmacy fulfillment, and scheduling on patients’ terms.

The initial laboratory panel costs $99 to $129 and includes the lab test, the at-home nurse visit or in-clinic option, the medical intake, and the clinician review. Ongoing treatment starts at $199 to $235 per month and includes medication, quarterly at-home nurse blood draws, unlimited clinician consultations, follow-up care, medication management, and discreet shipping. There are no upsells or hidden fees.

The care process begins with a comprehensive blood panel to evaluate testosterone levels and related biomarkers. Patients can receive at-home nurse visits as early as the next day, with optional in-clinic laboratory testing available. Feel30’s licensed clinicians review results and issue prescriptions only when medically appropriate and aligned with established guidelines. Most patients complete their initial evaluation within 48 to 72 hours.

Feel30 is one of the only national TRT providers offering quarterly at-home phlebotomy included in the base membership price, positioning it as a leading option for men seeking convenient, medically supervised hormone therapy.

According to established Endocrine Society guidelines, testosterone therapy should only be prescribed after laboratory testing confirms low testosterone. Testosterone levels naturally decline with age, and clinically low levels may be associated with symptoms like fatigue, reduced libido, decreased muscle mass, increased body fat, and lower motivation. Enclomiphene may be used to increase endogenous testosterone production while preserving fertility.

“Many men experience delays in hormone evaluation because of limited appointment availability or the inconvenience of accessing laboratory services,” said Anneliese Cadena, AGNP-C, board-certified Nurse Practitioner and consultant for Feel30. “Telehealth combined with at-home diagnostics allows timely evaluation and guideline-based prescribing with ongoing medical oversight.”
Telehealth continues to increase in men’s hormone care as patients seek faster evaluation and more flexible access to licensed clinicians. Integrated care models allow clinicians to assess laboratory data remotely, prescribe treatment, and follow up with patients.

Media Contact: Thomas Phillips, support@feel30.com, 833-545-1589

**About Feel30** Feel30 is based in Austin, Texas. The platform provides evidence-based testosterone therapy, enclomiphene treatment, and men’s health services with all-inclusive pricing, at-home lab testing with nurse visits, unlimited clinician support, and fast U.S. pharmacy fulfillment. The company’s mission is to make evidence-based hormone care clearer, faster, and more accessible for busy men nationwide who refuse to wait.

Cision View original content:https://www.prnewswire.com/news-releases/feel30-launches-austin-based-telehealth-platform-for-evidence-proven-trt–integrated-at-home-phlebotomy-services-302646836.html

SOURCE Feel30

Market Opportunity
TRUST AI Logo
TRUST AI Price(TRT)
$0.2494
$0.2494$0.2494
+0.56%
USD
TRUST AI (TRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Cardano founder Charles Hoskinson says Web3-native platforms already operate at a scale traditional finance has yet to reach. Cardano founder Charles Hoskinson
Share
LiveBitcoinNews2025/12/27 07:59
Fed forecasts only one rate cut in 2026, a more conservative outlook than expected

Fed forecasts only one rate cut in 2026, a more conservative outlook than expected

The post Fed forecasts only one rate cut in 2026, a more conservative outlook than expected appeared on BitcoinEthereumNews.com. Federal Reserve Chairman Jerome Powell talks to reporters following the regular Federal Open Market Committee meetings at the Fed on July 30, 2025 in Washington, DC. Chip Somodevilla | Getty Images The Federal Reserve is projecting only one rate cut in 2026, fewer than expected, according to its median projection. The central bank’s so-called dot plot, which shows 19 individual members’ expectations anonymously, indicated a median estimate of 3.4% for the federal funds rate at the end of 2026. That compares to a median estimate of 3.6% for the end of this year following two expected cuts on top of Wednesday’s reduction. A single quarter-point reduction next year is significantly more conservative than current market pricing. Traders are currently pricing in at two to three more rate cuts next year, according to the CME Group’s FedWatch tool, updated shortly after the decision. The gauge uses prices on 30-day fed funds futures contracts to determine market-implied odds for rate moves. Here are the Fed’s latest targets from 19 FOMC members, both voters and nonvoters: Zoom In IconArrows pointing outwards The forecasts, however, showed a large difference of opinion with two voting members seeing as many as four cuts. Three officials penciled in three rate reductions next year. “Next year’s dot plot is a mosaic of different perspectives and is an accurate reflection of a confusing economic outlook, muddied by labor supply shifts, data measurement concerns, and government policy upheaval and uncertainty,” said Seema Shah, chief global strategist at Principal Asset Management. The central bank has two policy meetings left for the year, one in October and one in December. Economic projections from the Fed saw slightly faster economic growth in 2026 than was projected in June, while the outlook for inflation was updated modestly higher for next year. There’s a lot of uncertainty…
Share
BitcoinEthereumNews2025/09/18 02:59
Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

PANews reported on December 27 that Sharplink CEO Joseph Chalom stated that the surge in stablecoins, tokenized RWAs, and the growing interest from sovereign wealth
Share
PANews2025/12/27 08:15